Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Myokardia Inc    MYOK

MYOKARDIA INC (MYOK)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/10/2018 10/11/2018 10/12/2018 10/15/2018 10/16/2018 Date
50.48(c) 50.54(c) 52.95(c) 53.42(c) 56.94(c) Last
215 559 332 424 377 711 367 886 208 251 Volume
-1.77% +0.12% +4.77% +0.89% +6.59% Change
More quotes
Financials (USD)
Sales 2018 27,1 M
EBIT 2018 -81,4 M
Net income 2018 -79,5 M
Finance 2018 370 M
Yield 2018 -
Sales 2019 18,5 M
EBIT 2019 -128 M
Net income 2019 -136 M
Finance 2019 207 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 64,7x
EV / Sales2019 104x
Capitalization 2 124 M
More Financials
Company
MyoKardia, Inc. operates as a biopharmaceutical company.It engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases.The firm focuses on the treatment of heritable cardiomyopathies, genetically-driven forms of heart failure that... 
More about the company
Surperformance© ratings of Myokardia Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on MYOKARDIA INC
09/26MYOKARDIA : to Present at the 2018 Cantor Global Healthcare Conference
AQ
09/24MyoKardia to Present at the 2018 Cantor Global Healthcare Conference
GL
09/14MYOKARDIA INC : Entry into a Material Definitive Agreement, Creation of a Direct..
AQ
08/29MyoKardia to Present at Two Upcoming Investor Conferences in September
GL
08/24MYOKARDIA : New Insights on Disease Burden for Hypertrophic Cardiomyopathy Patie..
AQ
08/24MYOKARDIA : New Insights on Disease Burden for Hypertrophic Cardiomyopathy Patie..
AQ
08/23New Insights on Disease Burden for Hypertrophic Cardiomyopathy Patients Publi..
GL
08/14MYOKARDIA : to Present at the 2018 Wedbush Pacgrow Healthcare Conference
AQ
08/09MYOKARDIA : 2Q Earnings Snapshot
AQ
08/08MYOKARDIA : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
More news
Sector news : Bio Therapeutic Drugs
10/16Sanofi's Dupixent Shows Positive Headline Results in Two Phase 3 Studies
DJ
10/11GILEAD SCIENCES : Allogene's Upsized IPO Prices at High End of Range
DJ
10/05ABBVIE : Receives Health Canada Approval of Orilissa for Endometriosis Pain Trea..
DJ
10/04J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
RE
10/02GILEAD SCIENCES : Allogene Sets IPO at 16 Million Shares; Sees Pricing $16-$18
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
10/16MyoKardia nearly triples space in big move to Brisbane  
10/16Myokardia Inc $MYOK Given Average Recommendation of “Buy” by Analysts  
10/16MyoKardia nearly triples space in big move to Brisbane  
10/16Growing quickly, biotech heart drug developer $MYOK signs lease in new $HCP p..
4
10/16Growing quickly, biotech heart drug developer $MYOK signs lease in new $HCP p.. 
More tweets
Qtime:186
News from SeekingAlpha
10/01Premarket analyst action - healthcare 
09/28Premarket analyst action - healthcare 
09/10Premarket analyst action - healthcare 
09/06MyoKardia (MYOK) Presents At 2018 Wells Fargo Securities Healthcare Conferenc.. 
08/08MyoKardia (MYOK) CEO Tassos Gianakakos on Q2 2018 Results - Earnings Call Tra.. 
Chart MYOKARDIA INC
Duration : Period :
Myokardia Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MYOKARDIA INC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 77,0 $
Spread / Average Target 44%
EPS Revisions
Managers
NameTitle
Anastasios E. Gianakakos President, Chief Executive Officer & Director
June Lee Chief Operating & Development Officer
Taylor C. Harris Chief Financial Officer
Marc Semigran Chief Medical Officer
Mark L. Perry Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MYOKARDIA INC26.89%2 124
GILEAD SCIENCES1.59%95 398
VERTEX PHARMACEUTICALS20.99%46 338
REGENERON PHARMACEUTICALS2.18%40 777
NEUROCRINE BIOSCIENCES, INC.41.84%10 086
SAREPTA THERAPEUTICS INC136.05%8 671